A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
Status:
Suspended
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate an experimental drug called EZN-4176 to determine the anticancer
effects when it is given to patients with an advanced form of prostate cancer called
castration-resistant prostate cancer (CRPC). Goals of this phase I study include finding out
the dose of EZN-4176 that can be safely given without serious side effects and to determine
the amount of EZN-4176 that should be given in future studies.